Jivolar

Metformin Hydrochloride and Sitagliptin, the active ingredients in Jivolar, are a combined biguanide and DPP‑4 inhibitor presented as an oral tablet for oral use. They treat type 2 diabetes mellitus in adult patients by improving glycemic control. Metformin reduces hepatic glucose output while Sitagliptin enhances insulin secretion in a glucose‑dependent manner, together offering complementary mechanisms for blood sugar management.

GNH USA supplies Jivolar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for global healthcare providers.

Jivolar, a combination antidiabetic medication, is used to manage type 2 diabetes mellitus and related glycemic targets. - Type 2 diabetes mellitus: improves overall blood glucose control when combined with diet and exercise. - Inadequate control on metformin alone: adds DPP‑4 inhibition to achieve target HbA1c. - Adjunct to insulin therapy: helps reduce required insulin dose and stabilizes glycemic fluctuations.

Jivolar may be associated with a range of adverse reactions, which are categorized by frequency and severity. Common Side Effects: - Nausea: mild gastrointestinal upset. - Diarrhea: loose stools. - Headache: mild tension‑type headache. Serious or Rare Side Effects: - Lactic acidosis: severe metabolic acidosis requiring urgent care. - Pancreatitis: abdominal pain with elevated pancreatic enzymes. - Severe allergic reactions: rash, angioedema, or anaphylaxis.

When prescribing Jivolar, clinicians should consider several precautionary measures to minimize risks. - Renal function: assess baseline creatinine clearance and monitor periodically. - Lactic acidosis risk: avoid in patients with severe renal impairment or hepatic disease. - Hypoglycemia risk: monitor closely when used with insulin or sulfonylureas. - Pregnancy: safety not established; use only if potential benefit justifies potential risk. - Vitamin B12 levels: monitor during long‑term metformin therapy as deficiency may develop. - Store at ambient temperature: keep in original container, protect from moisture and heat.

Jivolar can interact with other medicines, influencing its efficacy or safety. Major Interactions (Avoid): - Insulin or sulfonylureas: increased risk of hypoglycemia. - Iodinated contrast agents: may precipitate metformin‑associated lactic acidosis. - Cimetidine: can raise metformin plasma concentrations. Moderate Interactions (Monitor Closely): - Rifampin: may reduce sitagliptin exposure, decreasing effectiveness. - Diuretics: may affect glucose control and electrolyte balance.